AI-generated analysis. Always verify with the original filing.
Satellos Bioscience Inc. filed its Form 40-F annual report for fiscal year 2025, covering the period ended December 31, 2025. This comprehensive filing includes the company's annual information form, audited financial statements, and management's discussion and analysis. The document reveals Satellos as an emerging growth company incorporated in Canada with its common shares traded on Nasdaq under ticker MSLE. Key financial disclosures show the company had 15,458,903 common shares outstanding as of the reporting period end. The filing incorporates exhibits containing detailed financial information, including balance sheets, income statements, and cash flow statements for 2025 and 2024, prepared under IFRS standards. The company's principal executive offices are located in Toronto, Ontario, with a U.S. subsidiary in Boston, Massachusetts. PricewaterhouseCoopers LLP served as the independent auditor for the financial statements. The filing indicates the company has met all SEC reporting requirements for the preceding 12 months and has submitted required Interactive Data Files. The document serves as the company's primary annual disclosure to U.S. regulators and investors, providing transparency about its financial condition, operations, and compliance status.